Cannara Biotech Inc
XTSX:LOVE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ecora Resources PLC
LSE:ECOR
|
UK |
|
BioArctic AB
STO:BIOA B
|
SE |
|
Liquidmetal Technologies Inc
OTC:LQMT
|
US |
|
BYD Co Ltd
OTC:BYDDY
|
CN |
|
K
|
Kernel Holding SA
WSE:KER
|
UA |
|
Reckitt Benckiser Group PLC
LSE:RKT
|
UK |
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
CA |
|
Corteva Inc
NYSE:CTVA
|
US |
|
A
|
Asseco Poland SA
WSE:ACP
|
PL |
|
S
|
Sotoh Co Ltd
TSE:3571
|
JP |
|
T
|
Tuya Inc
NYSE:TUYA
|
CN |
|
N
|
Nature Wood Group Ltd
NASDAQ:NWGL
|
MO |
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
C
|
Cannara Biotech Inc
XTSX:LOVE
|
173.7m CAD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
243.4B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
288B USD |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
225.4B CHF |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.5B USD |
Loading...
|
Market Distribution
| Min | -10 058.3% |
| 30th Percentile | 20.4% |
| Median | 33.6% |
| 70th Percentile | 50.5% |
| Max | 717.4% |
Other Profitability Ratios
Cannara Biotech Inc
Glance View
Cannara Biotech, Inc. is a pharmaceutical company, which operates cannabis biotech facility. The company is headquartered in Montreal, Quebec. The company went IPO on 2019-01-14. The firm operates through its wholly owned subsidiaries, Cannara Biotech (Quebec) Inc. and Cannara Biotech (Valleyfield) Inc. Its segments include Indoor cannabis operations and Real estate operations. The Indoor cannabis operations segment includes the cultivation, processing and sale of dried cannabis and cannabis derivatives exclusively for the Quebec and Canadian market. The Real estate operations segment is related to the Farnham building. The Company, through ShopCBD.com Inc., operates an online e-commerce platform in the United States hemp-based Cannabidiol (CBD) market. The firm sells dried cannabis products to provincial retail distributors and other licensed producers across Canada through Cannara Biotech (Quebec) Inc. The company owns approximately two cultivation facilities based in Quebec spanning over 1,650,000 square feet.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Cannara Biotech Inc is 17.9%, which is above its 3-year median of 11.3%.
Over the last 3 years, Cannara Biotech Inc’s Gross Margin has decreased from 18.1% to 17.9%. During this period, it reached a low of 5.6% on Aug 31, 2024 and a high of 18.1% on Nov 30, 2022.
